Three of Houston's mayoral candidates shared the stage at Tech Rodeo to talk about how they would lead the city toward greater success within the innovation space. Photo by Natalie Harms/InnovationMap

It's an election year in Houston, and one of the big topics on the minds of the candidates is how to continue the momentum of Houston's developing innovation ecosystem.

Houston Exponential put three of the declared candidates on the stage yesterday to ask them about their vision for Houston on the final day of Houston Tech Rodeo 2023. HX CEO Natara Branch moderated the discussion with Chris Hollins, Lee Kaplan, and Amanda K. Edwards. Each candidate addressed issues from diversity and equity, the energy transition, and more.

Missed the conversations? Here are a few overheard moments and highlights of the panel.

“It’s integral to our vision for the future of Houston that this is a place where small businesses, entrepreneurs, and creatives can thrive. We want to grow this economy to be one of the strongest economies in the United States — and we know that startups and small businesses are the powerhouse for that.”

— says Chris Hollins, who explains that he's a small business owner himself and also served as interim Harris County Clerk from June 2020 to November 2020, overseeing the 2020 United States presidential election in Harris County.

“Houston has an energy-centric community, and a lot of people who have money have gotten too comfortable investing in just oil and gas. … I understand how hard it is to run a business, and I understand (it) from representing entrepreneurs and investors.”

— says Lee Kaplan, a founding partner at law firm Smyser Kaplan & Veselka LLP.

“One of the things that’s important in a leader is making sure that they understand your issues, but most importantly that they can execute. That has been something that has been chief in concert in the way that I have served in public service, but of course the way that I’ve been a part of the startup economy.“

— says Amanda K. Edwards, who contributed to the establishment of the city’s tech and innovation task force as an at-large Houston City Council member. The task force resulted in the creation of HX Venture Fund and the Innovation District, she explains.

“When we think about cities that have done this really well — Silicon Valley, The Bay Area, Boston, Austin — what’s key in many of those cities is institutions around education. … We have to lean into Rice University and the University of Houston — making these centers for talent, excellence, and innovation so that we’re developing the thinkers, the engineers, the creators of the future, and then we’re giving your businesses a crop of new hires.”

— Hollins says responding to a question about Houston's challenges.

“The thing that I think is the most important for the city is to be rigorous with what we do. We’re not going to get around the fact that it’s hot and we have mosquitos. But we can sell the fact that we have a city that’s improving.”

— Kaplan says on Houston's progress.

“I don’t want to compete or lose to any city in America. When I think about Houston, I’m bullish. I know that we are the place that is home to innovation, and it’s about time that people know us as that."

— Edwards says, referencing how Houston is known nationally for its problems — she gives the example of Hurricane Harvey. “We have major challenges in our city, but we can innovate using our innovation economy to provide answers and solutions to them.”

“Energy has to be a part of our story. We are where we are today because we’re the energy capital of the world. And we know that the energy transition is happening, and if we don’t lean into that, our region stands to lose hundreds of thousands of jobs.”

— Hollins says on the types of emerging tech in Houston.

“You often hear it said that Houston is the most diverse city in the nation, but I pose this challenge: What good is it to be the most diverse if we’re not solving the challenges that diverse communities face? And that includes equity in tech. We have all of the raw ingredients here in the Houston community to make Houston the home of where tech and innovation is diverse and equitable.”

— Edwards says on Houston's diversity and the challenges the city faces.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston digital health platform Koda lands strategic investment

money moves

Houston-based advance care planning platform Koda Health has added another investor to the lineup.

The company secured a strategic investment for an undisclosed amount from UPMC Enterprises, the commercialization arm of the University of Pittsburgh Medical Center. The funding is part of Koda's oversubscribed series A funding round that closed in October, according to a release.

"UPMC Enterprises’ investment is a meaningful signal, not just to Koda, but to the broader market," Dr. Desh Mohan, chief medical officer and co-founder of Koda Health, said in the news release. "It validates that health systems are ready to invest in infrastructure that makes advance care planning work the way it should: proactively, at scale, and with the human support that these conversations require. Having UPMC Enterprises as a strategic investor puts us in a unique position to prove what's possible."

Koda has raised $14 million to date, according to a representative from the company. Its series A round was led by Evidenced, with participation from Mudita Venture Partners, Techstars and the Texas Medical Center last year. At the time, the company said the funding would allow it to scale operations and expand engineering, clinical strategy and customer success. The company described the round as a "pivotal moment," as it had secured investments from influential leaders in the healthcare and venture capital space.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, saw major growth last year, as well, and now supports more than 1 million patients nationwide through partnerships with Cigna Healthcare, Privia Health, Guidehealth, Sentara, UPMC and Memorial Hermann Health System.

The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April 2025 and with Epic Systems in July 2025. It also won the 2025 Houston Innovation Award in the Health Tech Business category. Read more here.

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”